The LentiVector® gene therapy platform for ocular disease: A clinical update

    loading  Checking for direct PDF access through Ovid


The LentiVector® Gene Therapy Platform for Ocular Disease: a clinical update Oxford BioMedica currently has three ocular therapies in clinical development using the LentiVector® platform: RetinoStat®, StarGenT and UshStat®, for the treatment of age-related macular degeneration, Stargardt macula dystrophy and Usher Syndrome 1B respectively. A clinical update of these trials will be given.

Related Topics

    loading  Loading Related Articles